Sponsored by
We featured this investigational oncolytic viral treatment in our SNO 2023 abstract highlights. Over 50 patients have now been treated with a single dose of CAN-3110 in the Phase 1b trial, and investigators have reported a near doubling of survival for recurrent high grade glioma (~12 months versus historical reports of 6 to 9 months). The next arm of this study will investigate use of up to six intra-tumoral injections of CAN-3110 over a four month period. We'll be watching this trial closely!